Comparing Efficacy and Safety of (Meropenem + Colistin) Versus (Imipenem/Cilastatin + Tigecycline) on Eradication of Multi-Drug Resistance Bacteria

计划入组 60 人 · 首次发布于 2026 年 4 月 13 日

Ventilator Associated Pneumonia by Multi-Drug Resistant Organism

计划入组 319 人 · 首次发布于 2022 年 9 月 22 日

Prevention of Nosocomial Infections (CleanKids)

计划入组 4,944 人 · 首次发布于 2017 年 12 月 4 日

camptothecin-olaparib multi-drug nanoparticle-drug conjugates

PSX-2000 MCP

AGL-503

UNION MULTI CULTURES GUADELOUPEENNE

Guadeloupe

HCG MULTI SPECIALTY HOSPITAL

India

Redpharm Drug

United States

Nanoformulation Strategies to Overcome Multi-Drug Resistance in Cancer: A Call for Pharmacological and Translational Rigor

Wockhardt's Novel Antibiotic 'Zaynich' Expected to Receive USFDA Approval in 2025

Lonza Grants Exclusive License to Antharis Therapeutics for Dual-Payload ADC Development in Gastrointestinal Cancers